Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

Abstract Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a “MITF‐high” phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also contain subpopulations of the de novo resistance “AXL‐high” p...

Full description

Bibliographic Details
Main Authors: Michael P Smith, Emily J Rowling, Zsofia Miskolczi, Jennifer Ferguson, Loredana Spoerri, Nikolas K Haass, Olivia Sloss, Sophie McEntegart, Imanol Arozarena, Alex vonKriegsheim, Javier Rodriguez, Holly Brunton, Jivko Kmarashev, Mitchell P Levesque, Reinhard Dummer, Dennie T Frederick, Miles C Andrews, Zachary A Cooper, Keith T Flaherty, Jennifer A Wargo, Claudia Wellbrock
Format: Article
Language:English
Published: Springer Nature 2017-08-01
Series:EMBO Molecular Medicine
Subjects:
AXL
BRAF
endothelin
melanoma
MITF
Online Access:https://doi.org/10.15252/emmm.201607156

Internet

https://doi.org/10.15252/emmm.201607156

Similar Items